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Abstract
Purpose—To quantify the influence of RS assay on changing chemotherapy plans in a general 
practice setting use using causal inference methods.
Methods—We surveyed 3,880 newly-diagnosed breast cancer patients in Los Angeles and 
Georgia in 2013-14. We used inverse propensity weighting and multiple imputations to derive 
complete information for each patient about treatment status with and without testing.
Results—Half of the 1,545 women eligible for testing (ER+ or PR+, HER2−, and stage I-II) 
received RS. We estimate that 30% (95% confidence interval (CI): 10% - 49%) of patients would 
have changed their treatment selections after RS assay, with 10% (CI: 0%-20%) being encouraged 
to undergo chemotherapy and 20% (CI: 10% -30%) being discouraged from chemotherapy. The 
subgroups whose treatment selections would be changed the most by RS were patients with 
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positive nodes (44%; CI: 24% - 64%), larger tumor (43% for tumor size >2 cm; CI: 23% - 62%) or 
younger age (41% for <50 years, CI: 23% - 58%). The assay was associated with a net reduction 
in chemotherapy use by 10% (CI: 4% - 16%). The reduction was much greater for women with 
positive nodes (31%; CI: 21% - 41%), larger tumor (30% for tumor size >2 cm; CI: 22% - 38%) or 
younger age (22% for <50 years; CI: 9% - 35%).
Conclusion—RS substantially changed chemotherapy treatment selections with the largest 
influence among patients with less favorable pre-test prognosis. Whether this is optimal awaits the 
results of clinical trials addressing the utility of RS testing in selected subgroups.
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Introduction
Breast cancer is an important paradigm for how advances in precision medicine may reduce 
overtreatment.[1,2] Results from 4 genomic tests (ER/PR, HER2, 21-gene assay) and 
pathology largely determine clinician recommendations regarding adjuvant chemotherapy 
for most patients newly diagnosed with curable invasive breast cancer. The 21-gene 
recurrence score (RS) assay has rapidly diffused into clinical practice and is markedly 
influencing treatment decisions. Studies have reported correlates of the use of the RS assay, 
as well as the association of testing and test results with the use of chemotherapy.[3-8] 
Although the test results clearly influence clinician recommendations, how testing itself 
influences the receipt of chemotherapy in different clinical subgroups in a community 
population has not been quantified. This question is particularly important as gene 
expression testing diffuses more broadly into the population.[9,10]
Selection effects confound the estimates of how testing influences receipt of chemotherapy 
because testing is not offered randomly. Patients are largely selected for testing by their 
physicians based on the pre-test likelihood of getting chemotherapy, which is influenced by 
clinical factors and patient preferences. Causal inference methods such as inverse propensity 
weighting can estimate the average causal effect of testing on chemotherapy use by 
attempting to create comparable groups of tested and un-tested people as in a randomized 
trial. However, these methods only estimate the net effect of testing on chemotherapy use, 
which can obscure the degree to which treatment plans are changed if, for a given 
population, there are changes in both directions in response to testing. It is also not possible 
to observe every patient’s treatment plan both with and without testing in a general practice 
setting in order to directly estimate the influence of testing.
We developed a method that enables more granular estimates of how the treatment plan 
would differ depending on whether a patient is tested or not, and for which patient sub-
groups RS testing most strongly influences the receipt of chemotherapy. We conducted our 
analysis using a large, diverse, contemporary population-based sample of patients newly 
diagnosed with early-stage breast cancer in 2013-14. We quantified 1) the overall change in 
chemotherapy use if the entire sample were tested with the RS assay and 2) the proportion of 
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patients whose treatment plan would be changed in each direction by RS testing, both 
overall and in subgroups of interest.
Methods
Data source
The iCanCare study identified women with early breast cancer who were aged 20 to 79 
years, diagnosed with ductal carcinoma in situ or invasive breast cancer, and reported to the 
Georgia or Los Angeles County Surveillance, Epidemiology, and End Results (SEER) 
registry. Patients were sent surveys approximately 2 months after surgical treatment between 
July 2013 and September 2014. Patients were excluded if they had prior cancer, stage III or 
IV cancer, tumors > 5 cm, or more than 3 positive lymph nodes. In Los Angeles County 
(only), Non-Hispanic Whites and African Americans under 50 were also excluded because 
of enrollment in other studies. African Americans and Latinas were oversampled in Los 
Angeles to ensure sufficient representation of minorities.
The registries identified eligible patients and administered the survey. Patients were sent a 
packet with a letter, survey materials, postage paid return envelope, and a $20 cash gift. A 
modified Dillman survey method was used to encourage response and telephone interviews 
were used when requested (median time from diagnosis to survey completion was 6 months, 
sd 2.8 months).[11]
A total of 3,880 patients were identified and sent a survey: 249 women were ineligible 
because they had exclusions noted above or were deceased, too ill to complete, or unable to 
complete a survey in Spanish or English); 2,587 of eligible patients (71%) completed the 
survey. Genomic Health, Inc. provided a database with the RS assay results, which was 
linked with patients in the iCanCare study and SEER data. The analytical sample was 
limited to 1,545 patients whose breast cancer was ER+ or PR+, HER2−, and stage I or II. 
The study protocol was approved by the University of Michigan, the University of Southern 
California, and Emory University.
Measures
The dependent variable was a binary variable that indicated the receipt of adjuvant 
chemotherapy via patient report. The primary independent variable was a binary variable 
indicating whether or not a patient received the RS assay. Covariates included patient 
demographics, clinical factors, and SEER site. Age at diagnosis, education, race/ethnicity, 
comorbidities, family income, insurance status, partner status, and employment status at 
diagnosis were obtained from surveys. Additionally, we asked patients how important it was 
for them to have as extensive treatment as possible and how important it was to have the 
newest and most advanced treatments. (5-point-response categories from “not at all 
important” to “very important”). The variables were dichotomized to be 1 if patients rated 
“quite important” or “very important” and 0 otherwise. Cancer stage, tumor grade, tumor 
size, lymph node status and progesterone receptor status were obtained from SEER clinical 
data.
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We first used inverse propensity weighting (IPW) to estimate the overall causal effect of the 
RS assay on the use of chemotherapy in the sample population.[12] The RS assay recipients 
were weighted by the inverse of the propensity score and the non-recipients were weighted 
by the inverse of one minus the propensity score. The propensity score was the probability 
of receiving the RS assay and calculated based on a logistic regression model. We included 
in the model the missing data patterns in addition to the covariates that affected either the RS 
assay or chemotherapy usage.[13] The distributions of covariates between the RS assay 
recipients and non-recipients before and after IPW were compared using the Mantel-
Haenszel test.
We then used a potential outcome multiple imputation approach (POMI) developed by us to 
estimate the causal effect (See Appendix), now including details about whether or not testing 
would change treatment plans at an individual level and in key clinical sub-groups. For this, 
we need to know the chemotherapy treatment status for each patient if tested with the RS 
assay, and if not tested. However, in a general practice setting, for each patient, the treatment 
status in only one of these two scenarios is available because she may not get tested; even if 
tested, her pre-test chemotherapy treatment plan is not usually available. Our approach uses 
sequential regression multiple imputation[14] to impute the unobserved (counterfactual) 
treatment status for each patient. Thus for patients who received the RS assay, we imputed 
their chemotherapy treatment status without the assay, and we did the reverse for those who 
were not tested. The multiple imputation method accounts for uncertainty associated with 
the prediction. Additionally, the method simultaneously handles missing data that occur in 
other measures. The imputation models included the same comprehensive set of variables 
used in the IPW method.
We classified patients into four groups according to how the assay would have influenced 
their chemotherapy plan: 1) those who would never receive chemotherapy whether tested or 
not (never-chemotherapy); 2) those who would have been treated without the test but would 
not if tested (chemotherapy-discouraged); 3) those who would not have chemotherapy 
without the test but who would if tested (chemotherapy-encouraged); 4) those who would 
receive chemotherapy with or without the test (always-chemotherapy).
POMI estimates the average causal effect of testing on chemotherapy use and the influence 
of testing by the direction and by the presence (vs. absence) of the causal effect of testing on 
treatment decisions. Both IPW and POMI methods minimize selection bias and control for 
observed confounders.
Results
The sample consists of 1,545 women who met selection criteria and were eligible to receive 
RS according to practice guidelines.[15] Of these patients, 764 (49.5%) received the RS 
assay. Table 1 shows that, after IPW, the distribution of patient characteristics appeared to be 
balanced between those tested and not tested. There was substantial overlap of the 
propensity scores between tested and non-tested populations. About one quarter (27%) of 
the sample were predicted to receive chemotherapy if everyone was tested and 37% to 
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receive chemotherapy if no one was tested. This corresponds to an overall net reduction of 
10% (95% CI: 4% - 16%) in chemotherapy use.
Using the POMI method, we show that about 20% (95% CI: 10% -30%) of patients would 
have been discouraged to receive chemotherapy (chemotherapy-discouraged) and 10% (95% 
CI: 0%-20%) encouraged to receive it (chemotherapy-encouraged) because of the influence 
of the RS assay (Figure 1). Thus, RS assay would have changed chemotherapy plan of 30% 
of patients (95% CI: 10% - 49%) and resulted in a 10% (95% CI: 4% - 16%) net reduction. 
The subgroups whose treatment plans would be changed the most by RS assay were patients 
with positive nodes (44%; 95% CI: 24% - 64%), larger tumor (43% for tumor size > 2 cm; 
95% CI: 23% - 62%) or younger age (41% for < 50 years, 95% CI: 23% - 58%). They were 
more likely to be “chemotherapy discouraged” and less likely to be “chemotherapy 
encouraged” than their counterparts. Across almost all subgroups except for tumor size <1 
cm, patients were more likely to be chemotherapy-discouraged than chemotherapy-
encouraged by RS assay.
Table 2 shows that 54% (95% CI: 44% - 64%) of patients were classified to be in the “never 
chemotherapy” category and 16% (95% CI: 6% - 27%) in the “always chemotherapy” 
category, regardless of RS use. Women with older age, smaller tumors, or negative lymph 
nodes were more likely to be in the “never chemotherapy” group and their counterparts were 
more likely to be in the “always chemotherapy” group. However, for the remaining 
substantial 30% of the population, testing appears to have influenced decisions.
Figure 2 displays the causal effect, calculated as the net difference between the proportion of 
patients who would have been “chemotherapy encouraged” and those who would have been 
“chemotherapy discouraged”. Testing would reduce chemotherapy use by 22% (95% CI: 9% 
- 35%) for patients < 50 years old, 19% (95% CI: 10% - 27%) for patients aged 50-59, and 
7% (95% CI: 1% - 12%) for patients aged 60-69, but the effect of the RS assay was 
negligible among patients aged >70 with a reduction of 4% (95% CI: 0% - 9%). Testing led 
to much lower chemotherapy use among patients with positive lymph nodes (31% less, 95% 
CI: 21% - 41%), compared with a much smaller effect among patients with negative lymph 
nodes (5% lower, 95% CI: 2% - 9%). The RS assay effect also varied by tumor size: the 
largest reduction in chemotherapy use was among patients with a tumor >2 cm (30% lower, 
95% CI: 22% - 38%), as compared to 8% (95% CI: 0% - 14%) among those with a tumor of 
1-2 cm and no reduction with a tumor <1 cm.
Discussion
The rapid adoption of RS testing into clinical practice underscores the commitment of 
medical oncologists to adopt the most precise evaluative testing algorithms to direct 
treatment decisions for patients with breast cancer. However, no study has quantified the 
causal effect of the dissemination of RS testing on altering chemotherapy plans and usage 
both in a community population as a whole and in key clinical subgroups.
We show that if the entire population represented by our diverse, contemporary sample of 
breast cancer patients with favorable prognosis (ER+ or PR+, HER2−, and stage I or II) 
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were tested, RS testing would change treatment decisions in almost a third of patients. The 
change comprises 20% who were “chemotherapy-discouraged” by RS (a change in decision 
against chemotherapy) and 10% “chemotherapy-encouraged” (a change towards 
chemotherapy). Importantly, the subgroup whose decisions would be most likely to be 
changed by testing was patients with less favorable prognosis (Figure 2). For example, for 
node-positive women, testing would change chemotherapy treatment plans of 44%, with a 
net reduction of 31%. For patients aged < 50 years, the test changed treatment plans in 41%, 
with a net reduction of 22%; and these numbers were 43% and 30% in patients with tumor 
size > 2 cm.
This finding is consistent with the observational evidence that the majority of patients tested 
receive low recurrence scores, even among those with less favorable pre-test prognosis.[16] 
However, it provides a much better estimate less contaminated by selection effects related to 
who gets tested. Thus we see patients with less favorable prognostic factors due to 
demography (e.g., young age) or clinical factors (e.g., larger tumor size or positive lymph 
nodes) are more likely to receive chemotherapy in the absence of RS, and thus are more 
likely to be “chemotherapy discouraged” by favorable RS results.
A number of prior studies have looked at the observed relationship of RS test results to 
chemotherapy use, but have reported only on the observable, RS-tested population. Since RS 
test is not offered randomly, such estimates are subject to selection bias and cannot be used 
to measure the population-wide effect of rapidly disseminating RS use both within and 
outside groups recommended for testing. It is also not feasible to obtain patients’ treatment 
plans before and after testing in a general practice setting. The two largest observational 
studies sampled populations from SEER-Medicare (N=44,000) or selected cancer centers 
(N=7400). Dinan et al. found no effect of testing on chemotherapy in women over 65,[5] and 
Hassett et al. found an odds ratio of .7 for the association of testing with chemotherapy.[6] 
These large prior studies, however, are not population based, restricted by age, location or 
both, and other than the SEER-Medicare study, excluded node-positive women for whom an 
increasing amount of testing and RS-assay-based decision making is being done.
A number of studies have assessed the effect of RS testing on physician recommendations. 
Estimates for the proportion of cases in which testing would change the physician 
recommendation ranged from 33% to 43% of cases.[17,18] These studies help clarify pieces 
of the decision-making process but cannot estimate the overall effect of testing on 
chemotherapy use across entire eligible population. Prior results are somewhat higher than 
the estimates we found for overall rates of change in chemotherapy decisions (30%). These 
prior studies provide evidence only about the stated preferences of the oncologists rather 
than the revealed choices, which are imperfectly represented by the chemotherapy received 
as the end result of the entire decision-making process in all its complexity.
Our study has several advantages: it is large, based on sampling from population-based 
SEER registry data across all ages, 20-79, and supplemented by comprehensive survey 
information about the subjects. Our analysis used causal methods to optimally balance our 
rich set of covariates for comparisons between tested and un-tested subjects. This is done in 
an effort to create estimates as close as possible to those that would be obtained from a 
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randomized clinical trial, with virtually no selection bias affecting RS use. Our analyses also 
obtained more granular information about the direction and presence of the influence of 
testing on chemotherapy decisions. However, there are some limitations to our study. The 
results of our study are limited to two large geographic area of the United States. 
Furthermore, some patient groups were not available for our sample frame because of 
commitments to other studies (Non-Hispanic Whites and African Americans under age 50 in 
Los Angeles County). Our study is observational and does not account for unmeasured 
factors. However, a particular strength of our analysis is the adjustment for a rich set of 
observed covariates including detailed information about socioeconomic status, patient 
attitudes, preferences and disease status collected through patient surveys.
Implications for clinical practice
Our findings reinforce that major advances in precision evaluate testing in curable breast 
cancer have markedly improved targeting of treatment to need. In our study, RS testing 
influenced the targeting of treatment to need in nearly one third of patients. There is growing 
recognition of the need to address overtreatment in patients with favorable disease. A vital 
solution to this problem is to improve evaluative test algorithms in order to more accurately 
identify patients for whom treatment would have no benefit. Our results suggest that 
potential overtreatment in patients with the most favorable disease is already low and that 
the addition of RS testing in this clinical subgroup would yield a very small additional 
reduction in chemotherapy use. For example, the net effect of testing is about nil for patients 
over 65 with tumor size <1 cm and negative nodes. That this effect is not bigger, in part 
reflects the good news that relatively few of these patients would get chemotherapy, given 
current practice patterns, even in the absence of the more precise targeting that RS testing 
offers. However, clinicians may favor testing in these patients to identify the very few 
patients with high RS scores who would benefit by treatment or to assure patients who might 
be inclined towards chemotherapy that benefit would not outweigh risks.
Our results suggest that the biggest decrease in chemotherapy use as a result of RS testing 
would occur in patients with less favorable prognosis (e.g., those with demographic or 
anatomic factors suggesting worse outcome, such as young age or positive lymph nodes). 
There is mounting evidence that this may represent appropriate re-classification from higher 
to very low marginal benefit of adjuvant chemotherapy, as clinical trial-based evidence 
grows of the utility of genomic expression testing in clinical subgroups with less favorable 
pre-test prognosis.[9,10] However further refinement of the clinical utility of RS in these 
subgroups awaits the results of the RxPONDER trial,[19] and it is even possible that some 
patients with node-positive disease who currently undergo testing may be ultimately 
undertreated as a result of testing. The advantage of the methods used in this paper is that we 
can start to anticipate how the spread of testing may change treatment patterns across the 
population, and thus can consider the appropriateness of those changes earlier in the course 
of dissemination of the test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The proportion of patients who would have been either “chemotherapy encouraged” or 
“chemotherapy discouraged”: overall and by clinical subgroups
The “chemotherapy encouraged” refers to patients who would not have received 
chemotherapy without the RS test but would with the test; the “chemotherapy discouraged” 
includes patients who would have been treated with chemotherapy without the RS test but 
would not with the test.
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Figure 2. Causal effect, with 95% confidence intervals, of the RS assay on chemotherapy use: 
overall and by clinical subgroups
The causal effect measures the effect of the RS assay testing on chemotherapy use if the 
entire sample (or clinical subgroups) was tested compared to the situation when no one in 
the sample (or clinical subgroups) were tested. It is obtained using the POMI method 
detailed in the methods section.
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Age at diagnosis, years % % % <.0001 % % 0.59
 20-49 13.6 11.9 15.3 13.9 13.4
 50-59 27.6 23.6 31.7 26.8 26.6
 60-69 32.3 30.4 34.3 32.7 31.3
 70-79 26.5 34.2 18.7 26.6 28.7
Node Status <.0001 0.19
 Negative 75.2 66.8 83.8 74.7 71.9
 Positive 17.7 23.9 11.3 18.0 20.5
 Missing 7.1 9.2 5.0 7.3 7.6
Tumor Grade <.0001 0.40
 1 35.2 37.8 32.6 35.3 34.2
 2 48.7 44.2 53.3 48.0 47.7
 3 15.1 16.1 14.0 15.7 17.4
 Missing 1.0 1.9 0.1 1.0 0.7
Progesterone receptor 0.35 0.48
 Negative 10.4 11.1 9.7 9.9 9.2
 Positive 89.6 88.9 90.3 90.1 90.9
Cancer Stage <.0001 0.22
 I 68.2 64.2 72.3 68.2 65.4
 II 30.7 34.4 26.8 30.7 33.6
 Missing 1.2 1.4 0.9 1.1 1.0
Tumor Size, cm <.0001 0.94
 <1 30.1 37.3 22.8 30.6 30.6
 1-2 45.6 36.4 55.1 45.9 45.4
 2-5 23.5 25.5 21.5 22.9 23.5
 Missing 0.8 0.9 0.7 0.7 0.6
Comorbidities* 0.008 0.84
 0 main disease 72.9 70.7 75.3 72.4 71.6
 1 main disease 21.4 21.9 20.8 21.7 22.5
 >1 main diseases 5.7 7.4 3.9 5.9 5.9
Want Newest and Most Advanced
Treatment
0.12 0.92
 No 27.1 24.8 29.3 27.9 27.2





























 Yes 68.6 70.4 66.8 67.9 68.6
 Missing 4.3 4.7 3.9 4.2 4.2
Want Extensive Treatment 0.17 0.48
 No 55.7 53.7 57.9 56.3 54.3
 Yes 38.4 39.7 37.0 38.2 40.4
 Missing 5.9 6.7 5.1 5.5 5.4
Race/Ethnicity 0.0002 0.62
 White 56.8 52.1 61.7 56.3 54.7
 Black 15.3 15.6 14.9 15.5 17.5
 Latina 17.5 21.5 13.5 17.8 17.8
 Asian 7.4 8.1 6.7 7.3 7.3
 Missing 3.0 2.7 3.3 3.0 2.7
Education 0.015 0.45
 High school/GED or less 29.7 33.0 26.3 30.3 29.1
 Some college/technical
 school
31.9 31.9 31.9 31.1 32.7
 College graduate or higher 37.1 33.8 40.5 37.2 37.2
 Missing 1.3 1.3 1.3 1.5 1.0
Annual Family Income 0.0007 0.55
 <20,000 15.3 15.8 14.9 14.8 14.4
 20,000 - 60,000 27.3 30.1 24.5 27.5 29.7
 >60,000 38.1 33.2 43.1 37.6 36.9
 Missing 19.3 21.0 17.5 20.2 18.9
Insurance Status <.0001 0.58
 No Insurance 0.5 0.4 0.7 0.4 0.7
 Public Insurance 44.7 50.7 38.6 46.2 44.9
 Private Insurance 51.1 45.2 57.1 49.2 50.7
 Missing 3.7 3.7 3.7 4.2 3.7
Partner Status 0.006 0.67
 No 35.7 39.3 31.9 35.4 35.7
 Yes 62.9 59.7 66.2 62.9 63.0
 Missing 1.4 1.0 1.8 1.7 1.3
Employment at Diagnosis 0.0016 0.21
 Unemployed 21.8 21.5 22.1 21.0 21.2
 Full Time 38.8 34.7 42.9 37.9 38.1
 Part Time 11.8 12.4 11.1 12.3 10.1





























 Retired or Not working 27.6 31.4 23.8 28.8 30.7
Site <.0001 0.87
 Georgia 54.9 44.3 65.7 55.1 54.8
 Los Angeles County 45.1 55.7 34.3 44.9 45.2
*
Comorbidities: 0, 1, 2 or more of the four major comorbid conditions: stroke, myocardial infarction, diabetes, or chronic obstructive pulmonary 
disease
§
RS assay: 21-gene recurrence score assay
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Table 2
The Percent of Patients, with 95% Confidence Intervals, in Each of the Four Groups* According to How the 
RS Assay
§









Overall 54.1 (44.0, 64.2) 19.9 (10.0, 29.9) 9.5 (0, 19.6) 16.4 (6.3, 26.5)
Age at diagnosis, years
 20-49 25.9 (15.7, 36.1) 31.4 (23.5, 39.2) 9.3 (0, 22.5) 33.5 (21.8, 45.1)
 50-59 43.5 (27.9, 59.1) 27.2 (12.0, 42.4) 8.4 (0, 20.9) 21.0 (8.9, 33.1)
 60-69 55.9 (44.4, 67.3) 18.3 (6.1, 30.4) 11.7 (1.6, 21.7) 14.2 (2.8, 25.6)
 70-79 74.2 (67.4, 81.0) 11.6 (4.0, 19.1) 7.5 (1.3, 13.7) 6.7 (0, 14.3)
Tumor Grade
 1 71.7 (63.9, 79.6) 16.5 (8.3, 24.7) 6.5 (0.3, 12.8) 5.3 (0, 12.3)
 2 53.7 (42.0, 65.4) 21.9 (11.8, 32.0) 10.5 (0, 22.6) 13.8 (2.8, 24.9)
 3 14.4 (0.5, 28.4) 21.3 (4.2, 38.5) 13.5 (0, 27.2) 50.7 (33.8, 67.6)
Tumor Size, cm
 <1 75.2 (66.4, 84.0) 7.9 (2.2, 13.5) 12.0 (2.3, 21.6) 5.0 (0, 11.4)
 1-2 56.7 (45.7, 67.6) 18.2 (5.2, 31.2) 9.8 (0, 20.7) 15.3 (2.0, 28.6)
 2-5 26.2 (14.0, 38.4) 36.3 (25.9, 46.8) 6.4 (0, 17.3) 31.1 (22.1, 40.0)
Node Status
 Negative 63.5 (53.3, 73.7) 15.7 (5.4, 26.0) 10.3 (0.2, 20.3) 10.5 (0.3, 20.7)
 Positive 15.1 (5.7, 24.4) 37.3 (25.3, 49.4) 6.5 (0, 17.0) 41.1 (28.3, 54.0)
*
Patients were classified into four groups according to the direction and presence of the influence of RS assay on chemotherapy treatment plan: 1) 
never chemotherapy: those who would never take chemotherapy whether tested or not; 2) chemotherapy discouraged: those who would have been 
treated without the test but would not if tested; 3) chemotherapy encouraged: those who would not have chemotherapy without the test but who 
would if tested; and 4) always chemotherapy: those who would take chemotherapy with or without the test.
§
RS Assay: 21-gene recurrence score assay
Breast Cancer Res Treat. Author manuscript; available in PMC 2018 February 01.
